-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Recently, Fosun Pharma issued an announcement stating that it has initiated a phase II clinical study of FCN-159 tablets for the treatment of type I neurofibromas
FCN-159 is an innovative MEK1/2 selective inhibitor independently developed by Fosun Pharma.
Currently, the MEK inhibitors that have been marketed globally include Pfizer's smetinib and binitinib, Exelixis' cobitinib, and Tobacco's trametinib
As of October 2021, Fosun Pharma’s current cumulative R&D investment for this new drug is RMB 108.